Inflammatory Bowel Disease

A majority of patients with ulcerative colitis treated with Xeljanz achieved clinical response after 8 or 16 weeks induction, according to study results.

In this Commentary, Gilaad G. Kaplan, MD, of the department of medicine, University of Calgary, Alberta, Canada, discusses the four epidemiological stages of inflammatory bowel disease (IBD) and reviews the forecast of disease prevalence and how disease penetration through a population evolves over time.

How common is asymptomatic bowel involvement in patients with peripheral or axial SpA? Can we use NSAIDs in these patients? What’s the difference between sulfasalazine and mesalamine? Hear what a rheumatologist should know about IBD!

Ustekinumab safely maintained a long-term clinical response and remission in patients with Crohn’s disease and ulcerative colitis, according to a presentation at the American College of Gastroenterology Virtual Annual Scientific Meeting.

This award goes to a patient advocate or advocacy group that moved the needle on a disease regarding discussion in the public sphere, better communication between patients and providers and/or advocacy for legislative or regulatory action.

This award goes to a gastroenterologist or hepatologist who consistently pushed the gastroenterology field forward through innovative treatments, practice management, patient care or research.

Patients with inflammatory bowel disease receiving long-term home parenteral nutrition via tunneled catheters had lower rates of DVT than those who used peripherally inserted catheters, according to research presented at the ACG Virtual Annual Scientific Meeting.

In an exclusive video, Rahul S. Dalal, MD, from Brigham & Women's Hospital in Boston, spoke about predictors of Stelara failure after dose intensification in patients with Crohn’s disease at the American College of Gastroenterology Annual Meeting.

In this exclusive video from the American College of Gastroenterology Virtual Annual Scientific Meeting, Laurie Keefer, PhD, from the Icahn School of Medicine at Mount Sinai discusses her presentation on the GRITT method, a resilience-based care model for patients with inflammatory bowel disease.

Congratulations to all our winners!